Skip to main content

Table 1 Baseline characteristics of study population stratified by AKI duration

From: Duration of acute kidney injury in critically ill patients

  SAILS patients AKI n = 238 Short duration AKI n = 76 Medium duration AKI n = 47 Persistent AKI n = 77 Death during AKI n = 38
Baseline characteristics
Age in years 54 [40, 66] 50 [40, 65] 53 [39, 65] 54 [40, 66] 58 [47, 68]
Female gender, n (%) 114 (47.9) 32 (42.1) 23 (48.9) 40 (51.9) 19 (50.0)
White race, n (%) 181 (76.1) 58 (76.3) 36 (76.6) 58 (75.3) 29 (76.3)
Hispanic or Latino, n (%) 32 (13.4) 14 (18.4) 7 (14.9) 8 (10.4) 3 (7.9)
BMI (kg/m2) 28.6 [23.6, 34.2] 28.0 [22.5, 33.3] 26.4 [22.8, 32.1] 30.5 [25.7, 34.6] 27.9 [24.0, 34.7]
Medical admission, n (%) 218 (91.6) 70 (92.1) 41 (87.2) 70 (90.9) 37 (97.4)
ICU days before study enrollment n (%) 1 [1, 2] 1 [1, 2] 2 [1, 3] 1 [1, 2] 2 [1, 2]
Rosuvastatin therapy, n (%) 120 (50.4) 33 (43.4) 19 (40.4) 46 (59.7) 22 (57.9)
Day of randomization APACHE III 98 [81, 121] 92 [78, 107] 91 [73, 112] 105 [89, 123] 121 [95, 139]
Comorbidities
Diabetes mellitus, n (%) 53 (22.3) 16 (21.1) 10 (21.3) 17 (22.1) 10 (26.3)
Hypertension, n (%) 112 (47.1) 35 (46.1) 20 (42.6) 35 (45.5) 22 (57.9)
Congestive heart failure, n (%) 16 (6.7) 2 (2.6) 5 (10.6) 8 (10.4) 1 (2.6)
Peripheral vascular disease, n (%) 12 (5.0) 4 (5.3) 3 (6.4) 4 (5.2) 1 (2.6)
Chronic pulmonary disease, n (%) 35 (14.7) 13 (17.1) 7 (14.9) 10 (13.0) 5 (13.2)
Cancer, n (%) 38 (16.0) 14 (18.4) 4 (8.5) 8 (10.4) 12 (31.6)
Day of AKI development
Study day that AKI developed 1 [1, 3] 2 [1, 3] 1 [1, 3] 1 [1, 2] 1 [1, 2]
Urine output (mL/kg/h) 0.78 [0.28, 1.48] 1.05 [0.70, 1.81] 1.36 [0.58, 2.87] 0.43 [0.06, 0.86] 0.31 [0.12, 0.88]
Platelets × 106/L 168 [74, 256] 204 [120, 292] 185 [115, 272] 143 [67, 220] 68 [26, 184]
Vasopressor use, n (%) 105 (44.3) 22 (28.9) 13 (27.7) 39 (51.3) 31 (81.6)
Systolic BP (mm Hg) 90 [80, 100] 94 [85, 105] 92 [82, 107] 86 [79, 98] 78 [70, 89]
PaO2/FiO2 ratio 155 [110, 220] 184 [129, 257] 192 [133, 272] 147 [106, 190] 123 [87, 151]
AKI characteristics
Baseline creatinine (mg/dL) 1.0 [0.7, 1.4] 0.9 [0.7, 1.4] 0.9 [0.6, 1.3] 1.2 [0.7, 1.9] 1.0 [0.7, 1.2]
Creatinine at AKI diagnosis (mg/dL) 1.7 [1.2, 2.6] 1.4 [1.0, 2.0] 1.4 [1.1, 2.0] 2.4 [1.6, 3.8] 1.8 [1.4, 2.4]
On dialysis, n (%) 25 (10.5) 1 (1.3) 0 (0.0) 18 (23.4) 6 (15.8)
KDIGO AKI stage at presentation
Stage 1, n (%) 172 (72.3) 72 (94.7) 40 (85.1) 35 (45.5) 25 (65.8)
Stage 2, n (%) 25 (10.5) 1 (1.3) 5 (10.6) 14 (18.2) 5 (13.2)
Stage 3, n (%) 41 (17.2) 3 (3.9) 2 (4.3) 28 (36.4) 8 (21.1)
KDIGO AKI maximum severity stage day 17
Stage 1, n (%) 116 (48.7) 63 (82.9) 31 (66.0) 13 (16.9) 9 (23.7)
Stage 2, n (%) 36 (15.1) 5 (6.6) 12 (25.5) 11 (14.3) 8 (21.1)
Stage 3, n (%) 86 (36.1) 8 (10.5) 4 (8.5) 53 (68.8) 21 (55.3)
  1. Continuous variables are presented as median and interquartile range
  2. AKI acute kidney injury, SAILS Statins for Acutely Injured Lungs from Sepsis, BMI body mass index, APACHE III acute physiologic and chronic health evaluation III, ICU intensive care unit, BP blood pressure, KDIGO kidney disease: improving global outcomes, PaO 2 /FiO 2 ratio partial pressure arterial oxygen/fraction of inspired oxygen